A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors

MC #23-26

NCT #
Condition(s)
Colorectal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC)
Molecular Target(s)
CD137, CEACAM5
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
LM-24C5
Phase(s)
I/II

Mechanism of Action

LM-24C5 is a CEACAM5 x 4-1BB bispecific antibody

Purpose

  • How much of the study agent can be given with an acceptable level of side effects
  • The effects of the study agent (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • How the study agent is acting on your body

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000